THE EFFICACY AND SAFETY OF ERDOSTEINE IN THE LONG-TERM THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). A 12-month, randomised, double-blind, placebo-controlled, parallel group, multicenter study.

Trial Profile

THE EFFICACY AND SAFETY OF ERDOSTEINE IN THE LONG-TERM THERAPY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD). A 12-month, randomised, double-blind, placebo-controlled, parallel group, multicenter study.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Mar 2017

At a glance

  • Drugs Erdosteine (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Registrational; Therapeutic Use
  • Acronyms RESTORE
  • Sponsors Edmond Pharma
  • Most Recent Events

    • 30 Sep 2015 Status changed from active, no longer recruiting to completed according to results presented at the 25th Annual Congress of the European Respiratory Society.
    • 12 Jun 2014 Planned End Date changed from 1 Apr 2012 to 1 Sep 2015, as per ClinicalTrials.gov record.
    • 12 Jun 2014 Status changed from recruiting to active, no longer recruiting, as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top